Skip to main content

Table 1 Clinical characteristic of patients

From: Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation

  ATG-6 ATG-10 P value
Subjects, n 29 31  
Age, years, median (range) 22 (16–48) 29 (15–48) 0.11
Gender, n (%)
 Male 18 (62.1) 24 (77.4) 0.19
 Female 11 (37.9) 7 (22.6)  
Diagnosis, n (%)
 AML 12 (41.4) 14 (45.2) 0.77
 ALL 12 (41.4) 12 (38.7)  
 CML 2 (6.9) 3 (9.6)  
MDS (RAEB) 3 (10.3) 2 (6.5)  
CD34+ cells in graft, ×106/kg, median (range) 2.4 (0.7–4.9) 3.1 (0.3–7.8) 0.32
Donor type Related donors  
HLA typing 1–3/6 Mismatch  
Stem cell source BM + PB  
Conditioning regimen BU + CY + ATG  
GVHD prophylaxis CSA + MMF + MTX  
  1. ATG antithymocyte globulin, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, BM bone marrow, BU busulfan, CML chronic myeloid leukemia, CSA cyclosporine A, CY cyclophosphamide, HSCT hematopoietic stem cell transplantation, MDS myelodysplastic syndrome, MMF mycophenolate mofetil, MTX methotrexate, PB peripheral blood
\